Peak HumanDatabase
    All Research
    PAPER LPA-20Review2025

    2024: the year in cardiovascular disease — the year of lipoprotein(a). Research advances and new findings

    Overview of 2024 Lp(a) advances including antisense (pelacarsen) and siRNA (olpasiran, lepodisiran, zerlasiran) therapies in phase 3 outcome trials.

    Evidence

    —

    Not Rated

    Sample

    —

    subjects

    Duration

    —

    study period

    Journal

    —

    Jan 2025

    03

    Structured Methods

    Study Design
    Review
    Sample Size
    Not reported
    Study Duration
    Not reported
    Methodology
    Not reported
    Limitations
    Not reported
    04

    Citations & References

    Cite this paper

    Unknown authors (2025). 2024: the year in cardiovascular disease — the year of lipoprotein(a). Research advances and new findings.

    Source

    Publisher

    05

    Indexing

    Biomarkers

    lp-a
    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation
    See your Peak Human Score How it works